Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Phase 2 Portion : Small Cell Lung Cancer(SCLC)”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Testing effectiveness (Phase 2)Study completedNCT02659059
What this trial is testing

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
Bristol-Myers Squibb 324
Testing effectiveness (Phase 2)Ended earlyNCT04260802
What this trial is testing

Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Who this might be right for
CancerNeoplasmsMetastatic Cancer+16 more
Ocellaris Pharma, Inc. 73
Testing effectiveness (Phase 2)Ended earlyNCT01898156
What this trial is testing

Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

Who this might be right for
Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), MesotheliomaPhase 2 Portion : Small Cell Lung Cancer(SCLC)
Kyowa Kirin Korea Co., Ltd. 37
Large-scale testing (Phase 3)Study completedNCT03098030
What this trial is testing

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer
United Therapeutics 483
Early research (Phase 1)Looking for participantsNCT07027514
What this trial is testing

Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Ankyra Therapeutics, Inc 60
Testing effectiveness (Phase 2)Study completedNCT03693612
What this trial is testing

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

Who this might be right for
Neoplasms
GlaxoSmithKline 26
Early research (Phase 1)Ended earlyNCT03116971
What this trial is testing

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

Who this might be right for
Small Cell Lung Cancer
EMD Serono Research & Development Institute, Inc. 2
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07739966
What this trial is testing

DS-3939a in Participants With Solid Tumors

Who this might be right for
Solid TumorLocally Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung Cancer
Daiichi Sankyo 400
Early research (Phase 1)Looking for participantsNCT07020117
What this trial is testing

[225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Who this might be right for
Urothelial Carcinoma BladderTriple Negative Breast Cancer (TNBC)Hormone Receptor Positive Breast Adenocarcinoma+4 more
Aktis Oncology, Inc. 150
Early research (Phase 1)Ended earlyNCT05621525
What this trial is testing

Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

Who this might be right for
Advanced Solid TumorAdvanced or Metastatic Non-small Cell Lung Cancer
LianBio LLC 7
Large-scale testing (Phase 3)Study completedNCT03409614
What this trial is testing

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Regeneron Pharmaceuticals 789
Testing effectiveness (Phase 2)Looking for participantsNCT06892548
What this trial is testing

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Who this might be right for
Advanced Lung Cancer
BioNTech SE 594
Testing effectiveness (Phase 2)Looking for participantsNCT07563738
What this trial is testing

A 2-part Phase 1/2 Open-label Trial on ODM-212

Who this might be right for
MesotheliomaPancreatic CancerNSCLC (Advanced Non-small Cell Lung Cancer)
Orion Corporation, Orion Pharma 229
Testing effectiveness (Phase 2)Active Not RecruitingNCT04440735
What this trial is testing

DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorNon Small Cell Lung CancerColorectal Cancer
Kahr Medical 125
Testing effectiveness (Phase 2)Study completedNCT00152477
What this trial is testing

Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

Who this might be right for
CarcinomaNon-Squamous Non-Small-Cell Lung Cancer
UCB Pharma 165
Early research (Phase 1)Study completedNCT03438318
What this trial is testing

Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Regeneron Pharmaceuticals 29
Testing effectiveness (Phase 2)Study completedNCT00842712
What this trial is testing

Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck KGaA, Darmstadt, Germany 232
Testing effectiveness (Phase 2)WithdrawnNCT05705466
What this trial is testing

Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Kartos Therapeutics, Inc.
Early research (Phase 1)Active Not RecruitingNCT04612751
What this trial is testing

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Advanced or Metastatic NSCLC
AstraZeneca 155
Early research (Phase 1)Ended earlyNCT04209465
What this trial is testing

BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Who this might be right for
Solid Tumor
Black Diamond Therapeutics, Inc. 91
Next Page